Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1467335 dose-ranging placebo-controlled phase IIa study in adults with clinical evidence of NASH
NL-OMON47669Phase 2Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing BI 1467335 multiple-dose arm(s) with Placebo (2 arms). Primary endpoint: Plasma AOC3 activity relative to baseline after 12 weeks. Started Jan 2019; status: active, not recruiting.
02
Drugs
PXS-4728A
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NL-OMON47669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47669.